Sam E. Khan, Partner - Mergers & Acquisitions, New York

New York / New Jersey

T: +1 646.414.6796 / +1 973.597.6372
F: +1 973.597.6373 skhan@lowenstein.com

New York / New Jersey

T: +1 646.414.6796 / +1 973.597.6372 | F: +1 973.597.6373 skhan@lowenstein.com

Related Areas

Education

Harvard Law School (J.D. 2009)

The University of Texas at Austin (B.A. 2005), Philosophy, History, and Arabic Language and Literature; summa cum laude; Phi Beta Kappa

Admissions

New York
New Jersey

BIO
EXPERIENCE
HONORS & AWARDS
NEWS & INSIGHTS

Filter By

Section

Type:

Practices:

Sectors:

Start Date:

End Date:

Sam Khan is often the first call his clients make when facing complex transactional challenges. He has represented a diverse range of clientele, including financial institutions, private equity and venture capital funds, large and middle market pharmaceutical companies, global chemical manufacturers, and media and entertainment businesses.

Sam concentrates his practice on mergers and acquisitions, joint ventures, strategic and commercial transactions, and also counsels clients on general corporate matters. Additionally, Sam has a wealth of experience in complex leveraged finance transactions, and restructuring and private investment transactions.

In every engagement, Sam relies on his sound business judgement and wealth of experience across a wide range of industries to provide his clients with practical and efficient advice, with a singular focus on their near and long-term business goals.

EXPERIENCE

Represented Cerity Partners in merger with AJ Wealth Strategies LLC, a New York-based investment and wealth management firm.
Represented Cerity Partners in merger with Gamble Jones Investment Counsel, a California-based investment and wealth management firm managing roughly $1.8B in client assets.
Represented Cerity Partners in merger with Ashfield Capital Partners, LLC, a San Francisco-based investment and wealth management firm that manages approximately $1.9B in assets.
Represented Cerity Partners in merger with ARGI Financial Group LLC, a Kentucky-based investment and wealth management firm that oversees $4.8B in assets.
Represented Cerity Partners in merger with Maryland Capital Management, LLC, an investment and wealth management firm.
Represented Cerity Partners in merger with Covington Capital Management, an investment and wealth management firm that manages approximately $1.9B in assets.
Represented Cerity Partners in merger with Round Table Services LLC, a California-based investment and wealth management firm.
Represented Hildred Capital Partners, LLC and its portfolio company Crown Laboratories, Inc. in Crown’s acquisition of the aesthetics-focused assets of Eclipse MedCorp, LLC, a medical technology company.
Represented Cloudmed, a New Mountain Capital portfolio company and leader in Revenue Intelligence™ solutions for healthcare providers, in its acquisition of par8o, an innovative healthcare technology company specializing in 340B and patient referral management technology for healthcare providers.
Represented Indorama Ventures (BKK:IVL) in its $2.1 billion acquisition of the specialty chemicals portfolio of Huntsman Corporation USA (NYSE:HUN).
Represented Indorama Ventures Corpus Christi Holdings LLC (subsidiary of Indorama Ventures Public Company Limited) in a joint venture between Indorama Ventures Corpus Christi Holdings LLC, DAK Americas, LLC (a subsidiary of the chemicals manufacturer Alpek S.A.B. de C.V. (BMV: ALFAA)), and APG Polytech USA Holdings, Inc. (a subsidiary of Far Eastern New Century Corporation (TT: 1402)), in the acquisition, through a bankruptcy auction, of a Corpus Christi, Texas-based PTA-PET plant from M&G USA Corp. (a subsidiary of M&G Chemicals), for a purchase price and capital contributions in the sum of $1.125 billion.
Represented Indorama Ventures Public Company Limited (BKK:IVL) as co-counsel with Mattos Filho in its acquisition of M&G Polimeros Brazil S.A., owner of Brazil’s largest PET (polyethylene terephthalate) facility.
Represented Covis Pharma B.V., a global specialty pharmaceutical company and portfolio company of Cerberus Capital Management, in its acquisition of certain assets from AstraZeneca AB for a closing cash purchase price of $350 million, in addition to conditional sales-related payments of up to $21 million.
Representing Indorama Ventures Public Company Limited (BKK:IVL) as co-counsel with Allen & Overy in its pending acquisition of DuPont Teijin Films. Lowenstein is leading the US components of the acquisition.
Represented Covis Pharma S.á.r.l and Covis Injectables S.á.r.l, global specialty pharmaceutical companies and portfolio companies of Cerberus Capital Management, in their all-cash $1.2 billion sale of assets to Concordia Healthcare Corp (TSX: CXR).
Represented BASF Corporation in the sale of its Polyolefin Catalysts business to W.R. Grace & Co., including BASF’s related technologies and production plants in Pasadena, Texas and Tarragona Spain.
Represented Metalico Inc. (MEA), one of the nation's largest scrap metal recyclers, in its execution of the merger agreement for the $102 million all-cash sale to Total Merchant Limited.
Represented Indorama Ventures Public Company Limited in its acquisition from BP Amoco Chemical Company of a 1,000-acre manufacturing facility located in Decatur, Alabama, which produces 1 million metric tons of annual purified terephthalic acid (PTA) capacity and 732,000 metric tons of paraxylene (PX) capacity.
Represented Crown Laboratories, Inc., a portfolio company of Hildred Capital Partners, LLC, in its acquisition of the North American distribution rights of five OTC consumer brands from GlaxoSmithKline.
Represented Crown Laboratories, Inc., a portfolio company of Hildred Capital Partners, LLC, in its acquisition of Vita Liberata, an Irish maker of sunless tanning and skincare products.
Represented Medical Specialties Distributors, LLC, a New Mountain Capital portfolio company, in its acquisition of First Choice Medical Holdings, Inc.
Represented BASF in its acquisition of Verenium Corp., a San Diego-based enzyme biotechnology company.
Represented Hildred Capital Partners, LLC and its portfolio company Crown Laboratories, Inc., a global innovative leader in the skincare industry, in Crown’s $924M merger agreement with Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.

HONORS & AWARDS

The M&A Advisor: THE M&A ADVISOR'S 14th ANNUAL TURNAROUND AWARDS (2019)
Chapter 11 restructuring of M&G Chemicals named winner of “Cross-Border Restructuring of the Year”

Chapter 11 reorganization of New England Motor Freight (NEMF) named winner of “Restructuring of the Year ($25M to $50M)”

CLICK HERE FOR AWARD INFORMATION & METHODOLOGY

No aspect of these advertisements has been approved by the highest court of any state.

NEWS & INSIGHTS

Education

Harvard Law School (J.D. 2009)

The University of Texas at Austin (B.A. 2005), Philosophy, History, and Arabic Language and Literature; summa cum laude; Phi Beta Kappa

Admissions

New York
New Jersey

Recent Searches

Relevant Insights

PROFESSIONALS | Lawyers

NEWS & INSIGHTS | Firm News

NEWS & INSIGHTS | Publications

Featured Content

CAPITAL MARKETS & SECURITIES / Firm News

PRO BONO / Report

LOWENSTEIN CRYPTO / Firm News

Sam E. Khan

Sam E. Khan

Related Areas

Education

Admissions

Filter By:

Filter By

EXPERIENCE

HONORS & AWARDS

NEWS & INSIGHTS

Education

Admissions

Related Areas

Recent Searches

Relevant Insights

PROFESSIONALS | Lawyers

NEWS & INSIGHTS | Firm News

NEWS & INSIGHTS | Publications

Featured Content

CAPITAL MARKETS & SECURITIES / Firm News

PRO BONO / Report

LOWENSTEIN CRYPTO / Firm News

Sam E. Khan

Sam E. Khan

Related Areas

Education

Admissions

Filter By:

Filter By

See more section

EXPERIENCE

HONORS & AWARDS

NEWS & INSIGHTS

Education

Admissions

Related Areas

Alternative Data = Better Investment Strategies, But Not Without Concerns

Alternative Data = Better Investment Strategies,
But Not Without Concerns